Peppermint Raises $4.7M Seed Led by Moxxie

TL;DR: Peppermint builds billing and collections software for clinical research. On October 8, 2026, Venture Capital Update reported that the company had raised a $4.7 million seed round led by Moxxie Ventures. The first outlet I found carrying the story was Pulse 2.0, and the company's own release is on Peppermint's site.

This is a small round in an unglamorous corner of healthcare, and I'm covering it because it shows what an early-stage check looks like when the product fixes a back-office problem rather than chasing headlines. It is a modest round.

Who put money into Peppermint?

Moxxie led. According to Pulse 2.0, Homebrew, Better Tomorrow Ventures, Layout Ventures, Digital Health Venture Partners and Night Capital participated, and angel investors Benjamin Mann and Evan Moore also took part.

That is a mix of generalist seed funds and a healthcare-focused investor, plus two individuals writing angel checks. If you invest at this stage, the angels are the part to study. They show how individuals get into a round that institutions lead.

Item	What was reported
Amount	$4.7 million seed
Lead	Moxxie Ventures
Participants	Homebrew, Better Tomorrow Ventures, Layout Ventures, Digital Health Venture Partners, Night Capital
Angels	Benjamin Mann, Evan Moore
Valuation	Not given in the sources I read

I found no valuation and no ownership split in any of those sources. Without them you can't judge whether the price was reasonable, so I'm treating that as an open question.

What does Peppermint actually do?

It handles money flow in clinical trials. Pulse 2.0 says its system pulls information from clinical trial management software, compares it with contracts and past payments, generates invoices, and manages collections. It pairs that software with human billing specialists.

The problem is real on the sites' side. The company's release cites a 2024 survey by the Society for Clinical Research Sites, which found that one-third of sites have more than 90 days of overdue receivables and half have three months or less of operating capital. Late payment can starve a research site. That gives a billing tool an obvious buyer, because every one of those sites is waiting on money it has already earned.

The founders are David Freeman and VJ Thurimella. Citybiz reports they met at X1, where they helped build the payments and reconciliation infrastructure behind a credit card business that Robinhood later acquired.

Do the results hold up?

I can only tell you what the company says. In its release, Peppermint states its partners collect revenue 3x faster, cut overdue invoices threefold and reclaim 20% of staff time spent on billing. Those numbers come from the company, with no named customers and no outside audit behind them that I could find. Weigh them accordingly.

Homebrew, one of the investors, wrote that the company has tripled the number of studies under management during the prior three months. Growth is happening, but off a base nobody has published. Tripling from a handful of studies is a very different thing from tripling from hundreds.

I signed off on more than 1,000 QA jobs in the Navy. The habit that stuck is separating what someone claims from what someone checked. Here, nobody outside the deal has checked anything.

What will the money be used for?

Per Venture Capital Update, the new capital will push Peppermint into budgeting, expense tracking and trial-level financial analytics. Moxxie's Alex Roetter put the opportunity this way: "There is no standard financial infrastructure for clinical trial billing today."

That is a lead investor describing its own thesis, so weigh it as such. It does tell you where the company is headed: from billing into the wider finance stack for research sites.

What this means if you invest at the seed stage

A $4.7 million round is roughly the size an accredited investor can follow through an angel group or syndicate. For comparison, I covered Quotr's $4M seed for AI construction estimating and Comparables.ai's $6M seed. At the other end of the market, Ramp's $750M round shows how differently late-stage money behaves.

Seed investing is a power-law game. Most companies at this stage return little, and a few carry the portfolio. This is educational, not a recommendation on Peppermint or any security.

Common mistakes when reading a seed announcement

The first is treating the round size as proof the product works. $4.7 million tells you what investors paid. It says nothing about whether hospitals keep renewing.

The second is trusting the headline metrics. Three-times-faster collection sounds strong, but without customer count, contract size or a baseline, you can't test it.

The third is skipping the missing pieces. No valuation, no revenue figure and no named customers means you are reading a press release, not a data room. Ask for those before you let a famous lead investor's name stand in for diligence.

FAQ

How much did Peppermint raise? Peppermint raised $4.7 million in seed funding, led by Moxxie Ventures, according to Pulse 2.0. The company announced it on October 8, 2026.

Who founded Peppermint? David Freeman and VJ Thurimella, who previously built payments and reconciliation infrastructure at X1 and Robinhood, per Peppermint's release.

What will Peppermint do with the money? It plans to expand into budgeting, expense tracking and trial-level financial analytics, according to Venture Capital Update.

What was Peppermint's valuation? The sources I read do not report one, so I can't tell you.

What to do today

Take the round's one figure you can verify, the $4.7 million, and write down the three numbers you would want before writing a check: valuation, customer count and revenue. If you can't get them, you have your answer on how much to trust the announcement. My free AIN briefing walks through this kind of seed-round check each week.

Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.